主辦機構:



HKU LKS Faculty of Medicine Department of Medicine 香港大學內科學系



2020網上公開講座

- 主題:高血壓與痛風
- 講題一:點解高血壓
 - 講者:張文勇教授 香港大學李嘉誠醫學院內科學系 孫建業心臟基金教授(心血管治療學)
- 講題二:如何正確治療痛風

講者:張錚醫生 香港大學李嘉誠醫學院內科學系 名譽臨床助理教授





HKU LKS Faculty of Medicine Department of Medicine 香港大學內科學系





點解高血壓


Professor Bernard M Y Cheung 張文勇教授

Division of Clinical Pharmacology & Therapeutics Department of Medicine University of Hong Kong

> 香港大學李嘉誠醫學院內科學系 孫建業心臟基金教授(心血管治療學)

Worldwide prevalence of hypertension 全球高血壓患病率

- Estimated to be 1.13 billion (2015)¹ 估計為11.3億(2015)
- 30-45% in adults¹ 成人30-45%







Hypertension: A Burning Health Problem

Hong Kong Centre for Health Protection Population Health Survey 2014/5 香港衛生防護中心人口健康調查(2014/5)

	Prevalence
Diagnosed hypertension 已確診的高血壓	14.6%
Undiagnosed hypertension 未確診的高血壓	13.2%
General obesity (BMI≥25) 普通型肥胖	30%
Hypercholesterolaemia (TC≥5.2) 高膽固醇血症	50%









Cheung et al. Am J Hypertens 2008; Ong et al. Hypertension 2006

ISH guideline: Classification of hypertension 國際高血壓學會 (ISH) 指南:高血壓的分類

ISH Category ¹ 分類	Systolic (mmHg) 收縮壓	Diastolic 舒張壓	(mmHg)
Normal BP 正常血壓	<130	and	<85
High-normal BP 血壓升高	130-139	and/or	85-89
Grade 1 Hypertension 1級高血壓	140-159	and/or	90-99
Grade 2 Hypertension 2級高血壓	≥ 160	and/or	≥100

Hypertension and CVD 高血壓與心血管疾病






Why do people have hypertension? 人們為什麼患有高血壓?

- Genetic factors 遺傳因素
- Environmental factors 環境因素

Genetic risk score involving 107 loci is associated with risk of hypertension and CVD



Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Warren et al. Nat Genet 2017

Anatomical and congenital causes Coarctation of the aorta 主動脈縮窄 解剖及先天原因 Renal artery stenosis 腎臟動脈狹窄 Polycystic kidneys 多囊性腎臟 Polycystic kidneys 多囊性腎臟 Renal causes Glomerulonephritis 腎小球腎炎 腎臟原因 Pyelonephritis 腎盂腎炎 Diabetic nephropathy 糖尿病腎病 Other causes of renal failure其他致腎衰竭的原因 **Endocrine causes** Hyperaldosteronism (including Conn's syndrome) 醛固酮增多症(包括康氏綜合症) 内分泌原因 Phaeochromocytoma 嗜鉻細胞瘤 Cushing's syndrome 庫欣綜合症 Acromegaly 肢端肥大症 Hyperparathyroidism 甲狀旁腺功能亢進 Vasculitis Systemic lupus erythematosus 系統性紅斑狼瘡 Polyarteritis nodosa 結節性多動脈炎 血管炎 Takayasu's disease 高安氏動脈炎 Corticosteroid 皮質類固醇 Drugs Oral contraceptive 口服避孕藥 藥物 Carbenoxolone 甘珀酸 Liquorice 甘草 Cyclosporin 環孢菌素

Secondary causes of hypertension 繼發性高血壓的原因


Environmental factors raising blood pressure 血壓升高的環境因素

- Obesity 肥胖
- Salt intake 鹽的攝入量
- Diet high in fat and low in fruits & vegetables 攝取高脂肪 和飲食缺乏水果和蔬菜
- Stress 壓力
- Alcohol 酒精






Strong relationship between blood pressure and obesity in the Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS)
香港心血管危險因素患病率研究(CRISPS)提示血壓與肥胖之間有密切關係



Obstructive sleep apnoea 阻塞性睡眠呼吸暫停



Hypertension as part of the metabolic syndrome 高血壓是代謝綜合症的一部分




- Abdominal obesity 腹型肥胖
- High blood pressure 高血壓
- High fasting plasma glucose 高空腹血糖
- ► Hypertriglyceridemia 高甘油三酯血症
- Low HDL-cholesterol 低HDL-膽固醇

How to treat hypertension?

怎麼治療高血壓?

International hypertension guidelines








ESC Europeen Heat journel (2016) 39, 3021-3154 of Cardology dol 50.109 36erteurojinty/379	ESC/ESH GUIDELINES
018 ESC/ESH Guidelines for	the management
of arterial hypertension	
The Task Force for the management of a suropean Society of Cardiology (ESC) an Hypertension (ESH)	
suthoru Task Force Menhens: Bryan Williams ⁴ (El iuseppe Hancis ¹ (ESH Charperson) (Uar), Wille Innic Agabia Rossel (Uar), Hichel Astu (France), enni L. Ciement (Belgium), Antonio Coca (Spain) and Dominizati (UK), Thomas Akahun (Sweden), here Redon (Spain), Luis Ruliope (Spain), Alberto trada), Swerz E. Kjolston (Noway), Reihold K rephane Laurent (France), Gregory T. H. Lip (UK) and E. Schmieder (Gerney), Ergery Shighko Jaka E. Schmieder (Gerney), Ergery Shighko Jaka E. Schmieder (Gerney), Ergery Shighko	s Spiering (The Netherlands), Michel Bumier (Switzerlands), Gioranni de Simone (Italy), Felix Mahfoud (Germany), Zanchetti (Italy), Mary Kerins reutz (Germany), Richard McManus (UK), Switzerland), (Russia), Costas Tsioufis
Composing actions, Bryon Williams, Institute of Candiovassian Science, University Callage London, H 7 (2014, UK, Tej. + H4 (2) 20 (2007) 900, E-mail Science/Amalgio Lauris, Grangon Plants, University Kentlanto Hubbinso of Plants, Verseis (198), Plazas del Davis, 4 – 20105 Plans, Italy, Tel. + 19 347 4021	of Hilano-Biccocx, Hilan, Italy: and Hypertaminer Career Intento

Thomas Unger, Claudio Borghi, Fadi C Dorairaj Prabhakaran, Agustin Ramire:	actice Guidelines harchar, Nadia A. Khaa, Neil R. Poulter, z, Markus Schlaich, George S. Stergiou, ford, Bryan Williams, Aletta E. Schutte
Table of Contents	Section 1: Introduction
Section 1. Introduction	Context and Purpose of This Guideline
Section 2. Definition of Hypertension	
Section 3. Blood Pressure Measurement and	Statement of Remit
Diagnosis of Hypertension	To align with its mission to reduce the global burden of raise
Section 4. Diagnostic and Clinical Tests	blood pressure (BP), the International Society of Hypertension (ISH) has developed worldwide practice guidelines for the
Section 5. Cardiovascular Risk Pactors	(ISH) has developed worldwide practice guidelines for the management of hypertension in adults, aged 18 years and
Section 7. Exacerbators and Inducers	management of hypertension in adults, aged 18 years an
of Hypertension	older. The ISH Guidelines Committee extracted evidence-base
Section 8. Treatment of Hypertension	content presented in recently published extensively reviewe
8.1 Lifestyle Modification 1341	guidelines and tailored COLORING and COLORING standard
8.2 Pharmacological Treatment	of care in a tractical format that is cary-to-use particularly
8.3 Adherence to Antihypertensive	in low, but also in high resource settings - by clinicians, but
Treatment	also nurses and community health workers, as appropriate
Section 9. Common and Other Comorbidities	Although distinction between low and high resource setting
of Hypertension	often refers to high (HIC) and low- and middle-income costs
Section 10. Specific Circumstances	tries (LMIC), it is well established that in HIC there are area
10.1 Resistant Hypertension	with low resource settings, and vice versa.
10.2 Secondary Hypertension	Herein optimal care refers to evidence-based standard o
10.3 Hypertension in Pregnancy	care articulated in recent guidelines ¹³ and summarized here
10.4 Hypertensive Emergencies	whereas CLILLIGAN standards recognize that COTTAIN
Hyperfersion 1350	standards would not always be possible. Hence essential stan
Section 11. Resources	dards refer to minimum standards of care. To allow specifica
Section 12. Hypertension Management at a Glance	tion of essential standards of care for low resource settings
Acknowledgments 1354	the Committee was often confronted with the limitation of
References 1354	absence in clinical evidence, and thus applied expert opinion
Beerinst March 6, 2020; free datation March 16, 2020; erwisen accepter Tenn the CARMS – School for Castlowardtar Diseases, Manatelda Uak Mathematical Diseases, Intel Castlowardtar Diseases, Manateldar Uak Mathematical Diseases, Intel Marchae, Mathematical Diseases, Annuel Parter, Diseases, et al. (2014). A school of the Castloward Disease Intel Disease Control, Nator National Castloward Diseases Parter Disease Control, Vender Marchae, Nationa Annuel, Angennia O, Marchae Disease, Control, Nator Nationa, Nationa Annuel, Angennia O, Marchae Disease Control, National Disease Annuel Angennia (National Disease). (2014) Erge Landon School Castloward Disease Tata Chineson (2014), National (National Disease Annuel Angennia (National Disease). (2014) Erge Landon School Castloward Disease National Castloward Disease (National Disease Annuel Angennia (National Disease Angennia). (2014)	1 March 27, 2020. ensity, the Netherlands (TLU): Department of Medical and Sargied Science bool of Health and Life Sciences, Ballana, Awaradia (FLC), University ruly of Licentur, Department of Cardiovancular Sciences, Valende Kingh (or Health Houldron and Ottorower Sciences, Nacorev, Canada (CAL)).

Received Ma From the CA University of 1 Matheears, Do GCA, University Unit, University Unit, University Methoume, Vic and Kapedintin, Matchester, Ut Trust Maachest (RLD W.) The Matheears, Vic Ma (RLD W.) Friculty of Mat and Hypertensi University, Post This article 5



- James PA et al. JAMA. 2014;311(5):507-520. 1.
- Whelton PK et al. Circulation. 2018;138(17):e484-e594. 2.
- Williams B et al. Eur Heart J. 2018;39(33):3021-3104. 3.
- Unger T et al. Hypertension. 2020;75(6):1334-1357. 4

ISH guideline: Blood pressure target ISH指南:血壓目標值

Essential 必要情況

- Target BP reduction at least 20/10mmHg, ideally to <140/90mmHg
- ・目標血壓降低至少20/10mmHg,理想情況下<140/90mmHg

Optimal 最佳情況

- <65 years old, BP target <130/80mmHg if tolerated (but >120/70mmHg)
- ・<65歲,如果耐受,血壓目標<130/80 mmHg(但> 120/70 mmHg)
- ≥ 65 years old, BP target <140/90mmHg but consider an individualized BP target in the context of frailty, independence and likely tolerability of treatment
- · ≥65歲,血壓目標<140/90mmHg,但在體弱、獨立和可能接受治療 的情況下考慮個體化的血壓目標

BP

Why non-pharmacological treatment is both Essential and Optimal

為什麼非藥物治療既是必需的又是最佳的

Non-pharmacological treatment saves treatment costs

非藥物治療節省了治療費用

 Non-pharmacological treatment improves blood pressure control and health outcomes

非藥物治療可改善血壓控制和健康狀況

 People with stage 1 hypertension (130-139/80-89 mmHg) should have non-pharmacological treatment in the first instance unless their CV risk is high

患有1期高血壓(130-139/80-89 mmHg)的人應首先接受非藥物治療,除非其心血 管風險很高

• Non-pharmacological treatment: its effectiveness and its costeffectiveness are variable, but it is safe

非藥物治療:其有效性和成本效益是可變的,但它是安全的

Lifestyle Modification 改善生活方式

Modification 改善方式 Weight reduction 減肥 DASH diet 抗高血壓飲食 Low sodium diet 低鈉飲食 Physical activity 體育運動 Moderate alcohol consumption


適度飲酒

Approximate SBP reduction 收縮壓大致降低程度

5-20 mmHg/10 kg weight loss 5-20毫米汞柱/10千克體重減輕 8-14毫米汞柱 2-8 mmHg 2-8毫米汞柱 4-9 mmHg 4-9毫米汞柱 2-4 mmHg




Strong relationship between blood pressure and obesity in the Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS)
香港心血管危險因素患病率研究(CRISPS)提示血壓與肥胖之間有密切關係





Krstic Z, 2020






© 2005 Encyclopædia Britannica, Inc.



Sodium intake & blood pressure 鈉攝入量和血壓



23

Commonly eaten foods high in sodium content 經常食用鈉含量高的食物



	Typical portion	Sodium
	content	
	(g)	(mmol)
Ham 火腿	40	23.1
Dim sum 點心	100	26.7
Marinated spare ribs 排骨	80	23.1
Chinese barbecue pork	80	36.9
叉燒		
Instant noodles 即食麵	100	49.6
Fish balls 魚丸	60	17.4
Sausages 香腸	34	19.1
Fried rice 炒飯	180	23.6
Preserved vegetables	40	37.7-140.6
醃製蔬菜		
Luncheon meat 午餐肉	28	16.2






ハジメの地球

Family medicine: complementary to personalised medicine 家庭醫學:個體化醫學的補充





Physical activity and mortality 體育活動和死亡率



LTPA leisure time physical activity 閒暇時間體育活動 OPA occupational physical activity 職業體育活動

Cheung et al. Korean Circulation J 2020

Lifestyle Modification 改善生活方式

Modification 改善方式 Weight reduction 減肥 DASH diet 抗高血壓飲食 Low sodium diet 低鈉飲食 Physical activity 體育運動 Moderate alcohol consumption


適度飲酒

Approximate SBP reduction 收縮壓大致降低程度

5-20 mmHg/10 kg weight loss 5-20毫米汞柱/10千克體重減輕 8-14毫米汞柱 2-8 mmHg 2-8毫米汞柱 4-9 mmHg 4-9毫米汞柱 2-4 mmHg



Number of antihypertensive drugs taken by patients in the Hypertension Clinic 高血壓病者服用的藥物數量




Disease 疾病	Drug Class	藥物種類			
Hypertension 高血壓	ARB	ССВ	ACEI	BB	Diuretic 利尿劑
	62.1	40.3	10.7	7.5	12.8

Data are expressed as percent. 表格中的數據皆使用百分比表示

ARB, angiotensin receptor blocker 血管緊張素受體拮抗劑. CCB, calcium channel blocker鈣通道 阻滞劑. ACEI, angiotensin-converting-enzyme inhibitor血管緊張素轉換酶抑制劑. BB, beta blocker β-受體阻滯劑.

Calcium channel blockers are effective in Hong Kong Chinese

鈣通道阻滯劑在香港人身上是有效的



Cheung et al. 1998

Common adverse effects of antihypertensive drugs 降壓藥的常見不良反應

Drug class 藥物種類	Adverse effects 不良反應	
Alpha ₁ -adrenergic antagonist	Postural hypotension	
Alpha ₁ -腎上腺素能拮抗劑	體位性低血壓	
ACE inhibitors	Cough, hyperkalemia, angio-oedema, creatinine rise	
ACE抑製劑	咳嗽,高鉀血症,血管性水腫,肌酐升高	
Angiotensin receptor blockers	Hyperkalemia, creatinine rise	
血管緊張素受體阻滯劑	高鉀血症,肌酐升高	
Beta-adrenergic blockers	Bradycardia, fatigue, heart block, bronchospasm, intermittent	
β-腎上腺素能阻滯劑	claudication, cold extremities	
	心動過緩,疲勞,心臟傳導阻滯,支氣管痙攣,間歇性跛行,四肢冷	
Calcium channel blockers	Flushing, headache, constipation, peripheral oedema, changes in	
鈣通道阻滯劑	heart rate	
	發紅,頭痛,便秘,周圍水腫,心率變化	
Diuretics, thiazide or thiazide-like	Hypokalemia, hyponatremia, hyperuricaemia, postural hypotension	
利尿劑,噻嗪或類噻嗪	低鉀血症,低鈉血症,高尿酸血症,體位性低血壓	


Summary 總結


- Hypertension is common. 高血壓很常見
- Genetics can make some people more likely to develop hypertension, but the major factor is sex, age and unhealthy lifestyle 遺傳因素可使某些人更容易患上高血壓,但主要的影響因素是性別、年齡和不健康的生活方式
- Using a combination of drugs, blood pressure is not hard to control in most patients 通過藥物聯合治療,大多數患者的血壓並不難控制
- Ask your doctor if you have questions about side effects 如果您對副作用有疑問,請咨詢您的醫生
- Lifestyle changes may prevent hypertension or make it easier to treat 生活 方式的改變可以預防高血壓或使其更容易治療
- Healthy diet and regular physical activity are beneficial, not just for the hypertensive patient but the whole family 健康的飲食習慣和規律的體育鍛煉 不僅對高血壓患者有益,而且對整個家庭有益

如何正確治療痛風


張錚醫生


香港大學李嘉誠醫學院內科學系 名譽臨床助理教授






痛風患者的男女比例














除高尿酸外, 還有其他導致痛風的因素嗎?





E












痛風的診斷(>8)










急性自動的徐療

e







藥物的副作用是選擇的關鍵

非類固醇消炎止痛藥

- ・胃炎、胃潰瘍、胃出血
- ·影響腎功能
- · 增加心血管病的風險


秋水仙鹼

- ·與其他藥物有相互作用
- · 腎功能差可增加藥物副作用的風險



何時需要服用降尿酸藥物?





有關高尿酸的其他不良影響

レ

尿酸值每高出 1mg/dL, 高血壓風險 增加13%




患心血管病的風險增 加46%


•

因心血管病的死亡率 增加34%




患中風的風險增加 41%





戒口可減低痛風發作, 但不能有效降低血尿酸的水平


嘌呤在體內的新陳代謝

















嚴重藥物敏感




遺傳基因測試

別嘌醇敏感

遺傳基因是對別嘌醇 敏感最主要的原因




在中國人中有 HLA-B*5801的機會 對別嘌醇敏感患者中有 HLA-B*5801的機會






血液尿酸水平應控制在 6mg/dL或360mmol/L以下


血尿酸水平和死亡率的關係





別嘌醇與非布司他的比較




別嘌醇與非布司他的比較








香港痛風患者的尿酸水平



痛風患者控制尿酸的情況






如何有效預防痛風發作



血尿酸降至治療目標 適當的飲食控制



適當的飲食控制







- 戒口可減低痛風發作,但不能有效 降低血液尿酸的水平
- 痛風患者應盡早長期服用降尿酸 藥
- 長期服用降尿酸藥可以降低心血 管病和慢性腎病的風險
- 血液尿酸水平應控制在6mg/dL或 360mmol/L以下